 |
|
|
|
 |
A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
[Protocol 09-035]
- Full Title :
- A PHASE I DOSE ESCALATION STUDY USING ULTRA-HYPOFRACTIONATED, IMAGE-GUIDED, INTENSITY-MODULATED RADIOTHERAPY IN PROSTATE CANCER
- Purpose :
Image-guided intensity-modulated radiation therapy (IG-IMRT) is a form of radiation therapy to treat prostate cancer. Typically, this treatment requires patients to come in for one-hour radiation therapy sessions five days a week for eight to nine weeks.
The purpose of this study is to evaluate the side effects associated with escalating doses during a shorter course of radiation therapy called ultra-hypofractionated IG-IMRT in men with prostate cancer. This therapy is delivered every other day for a total of five treatments which can be completed within two weeks.
The radiation delivered during ultra-hypofractionated IG-IMRT is a higher, more targeted dose than the conventional approach. By the end of treatment, patients should receive a total radiation dose that is equal to or greater than the standard approach.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of low-risk or intermediate-risk prostate cancer and be candidates for radiation therapy.
- Patients may not have had prior hormonal therapy for prostate cancer.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Brett W. Cox at 212-639-5717.
|
|
|
|
|
